US Bancorp’s Bionano Genomics BNGO Stock Holding History

US Bancorp’s Portfolio BNGO Stock Details BNGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-4	Closed	-$2.41K	–	4005
2023 Q1	$2.41K	Hold	4	–	–	﹤0.01%	3712
2022 Q4	$3.21K	Hold	4	–	–	﹤0.01%	3649
2022 Q3	$4K	Sell	4 -4	-50%	-$5.29K	﹤0.01%	3649
2022 Q2	$6K	Buy	+8	New	+$8.23K	﹤0.01%	3506
2021 Q2	–	Hold	0	–	-$1K	–	3998
2021 Q1	–	Hold	0	–	–	–	3771

Other funds holding BNGO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $149B AUM 24.71% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

US Bancorp's BNGO Position: Q2 2023 in Review

US Bancorp sold out of Bionano Genomics (BNGO) in Q2 2023, closing a stake of 4 shares — an estimated $2.41K sold.

US Bancorp first reported a position in BNGO in Q2 2022 and held it in 4 quarters. The position peaked at $6K in Q2 2022. 108 funds tracked by Wall St. Rank hold BNGO as of Q2 2023.

US Bancorp reported no remaining Bionano Genomics position as of Q2 2023 after selling out during the quarter.
US Bancorp sold 4 Bionano Genomics shares in Q2 2023, an estimated $2.41K.
US Bancorp first reported a position in Bionano Genomics in Q2 2022 and held it in 4 quarters.
US Bancorp's Bionano Genomics position peaked at $6K in Q2 2022.
108 funds tracked by Wall St. Rank held Bionano Genomics as of Q2 2023.

Based on US Bancorp's 13F filing for Q2 2023, filed 10 Aug 2023.